跳至主要内容
临床试验/NCT03363451
NCT03363451Unknown不适用

A Retrospective Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIR Study)

Tongji Hospital1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2018年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
2,000
试验地点
1
主要终点
Complete response rate to empirical antibiotic treatment

研究概览

简要总结

The term of End Stage of Liver Disease (ESLD) was raised in 80's of 20 Century, but without a restrict definition. Infections are the cause and effect in occurrence and development of ESLD, which not only induce or exacerbate ESLD, but also are the most combined complication. Multi-resistant bacteria, multi-organ injury, selection of anti-microbes, supporting treatment, disorder of intestine microbiota, et al are dilemma in clinical practice. Appropriate and formal diagnosis and treatment of ESLD combined infection are imperious nowadays.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Decompensation of liver cirrhosis:
  • ALB <35 g / L; A / G <1.0
  • TBIL> 35μmol / L;
  • ALT> 1 × ULN and / or AST> 1 × ULN
  • Ascites or hepatic encephalopathy or esophageal variceal bleeding
  • Acute-on-chronic liver failure:
  • Chronic liver disease based on: chronic hepatitis or decompensated cirrhosis
  • onset time: <4 weeks
  • Hepatic encephalopathy: with or without
  • Coagulation: PTA ≤ 40% or INR ≥ 1.5
  • Jaundice: TBIL ≥ 171μmol / L or daily increase ≥ 17.1μmol / L
  • Chronic liver failure:
  • The basis of chronic liver disease: decompensated cirrhosis
  • onset time: -
  • Hepatic encephalopathy: with or without
  • Coagulation: PTA ≤ 40% or INR ≥ 1.5 Jaundice: significantly higher

排除标准

  • 未提供

研究组 & 干预措施

Infection Group

Patients with end stage liver disease with infection

干预措施: Antibiotics (Drug)

结局指标

主要结局

Complete response rate to empirical antibiotic treatment

时间窗: 6 months

The percentage of patients who achieved complete recovery from combined infection after empirical antibiotic treatment

次要结局

  • Non-liver transplant survival(6 months)
  • Hospitalization time(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Qin Ning

Director of Department of Infectious Disease

Tongji Hospital

研究点 (1)

Loading locations...

相似试验